CERA

Science and Research

CANBERRA: A randomized, double-masked, 48-week, parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve diabetic retinopathy

Overview

  • Principal Investigator
Associate Professor Sanj Wickremasinghe